January 24, 2025 10:53 GMT
HEALTHCARE: Novo Nordisk (NOVOB: Aa3/AA-): Amycretin Success
HEALTHCARE
- "*NOVO NORDISK SHARES RISE 8.1% AFTER AMYCRETIN TRIAL RESULTS" - BBG
- Amycretin is dual-action weight-loss drug which work both as a GLP-1 and Amylin agonist.
- Credit isn't really going to rally given where NOVOB trades. This is more about maintaining a strong position.
41 words